Trobalt® (retigabine): Risk of pigmentary changes
2013.06.24
Active substance: retigabine
The company GlaxoSmithKline is sending out information that treatment with the medicinal product Trobalt® can lead to pigmententary changes of eye tissues, including the retina, as well as of the skin, lips and/or nails.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN